Fig. 8

Potential role of the risk score in mutation and drug therapy. (A) Frequency of somatic mutation in different risk groups. (B) Survival analysis of the tumor mutation burden. (C) Subgroup survival analysis of the tumor mutation burden and the risk score. (D) Sensitivity analysis to chemotherapy and targeted therapy in different risk groups (including sorafenib, 5-fluorouracil, doxorubicin, mitomycin C, bortezomib, and vinblastine). The above P < 0.05 was considered statistically significant